Protection against Divergent Influenza H1N1 Virus by a Centralized Influenza Hemagglutinin
Figure 3
Adenovirus as a platform for Influenza vaccines.
Prophylactic responses in mice immunized with consensus and wildtype adenoviral vectors were determined by immunizing mice with 1010 Ad vaccine viral particles. Three weeks after immunization the mice were challenged intranasally with 100 MLD50 of influenza A/PR/8/34 virus (A). In order to determine how much ad vaccine would be required to induce prophylaxis, mice were immunized intramuscularly with 10-fold dilutions of adenovirus expressing the A/PR/8/34 HA and challenged with 100 MLD50 of influenza A/PR/8/34 virus 3 weeks later (B). In order to determine the length of time to induce prophylaxis and the duration of prophylactic immune responses using Ad vaccines, mice were immunized intramuscularly with 1010 vp of Ad expressing A/PR/8/34 HA. The mice were challenged intranasally with 100 MLD50 of influenza A/PR/8/34 virus 1, 3, 5 and 200 days post immunization (C). Weight loss and survival were monitored daily. Mice that lost more than 25% of their baseline weight were humanely sacrificed.